工程化阴性介质素-1受体对手在关节保留和预防IL-1诱导的软骨炎症方面表现优于anakinra
Timothy L Boyer1, Bill Hakim1, Luke Childress2
1Department of Bioengineering, Northeastern University.
Osteoarthritis and cartilage
|December 26, 2025
概括
工程化阴性介质素-1受体对手 (catIL-1RA) 显示改善了关节保留,并防止了骨关节炎的进展. 这种新的生物策略增强了疾病修饰性关节炎药物 (DMOADs) 的药物输送.
科学领域:
- 生物材料科学 生物材料科学
- 药物输送系统 药物输送系统
- 骨关节炎治疗药物 治疗药物
背景情况:
- 骨关节炎 (OA) 的关节内疗法患有快速清除和关节保持不良.
- 制定提高关节内的药物生物可用性的策略对于有效的OA治疗至关重要.
研究的目的:
- 为改进软骨向和保留而设计一个阴阳性互乐金-1受体对手 (catIL-1RA).
- 在临床前OA模型中,比较catIL-1RA与标准IL-1RA (Anakinra) 的疗效.
主要方法:
- 计算机建模指导了catIL-1RA的设计,使用软骨向化载体 (CPC).
- 评估了受体结合亲缘关系,大鼠OA模型中的药理动力学,以及在牛实验体中预防IL-1诱导的软骨代谢.
主要成果:
- catIL-1RA表现出与阿纳金拉相似的受体结合.
- 与Anakinra相比,catIL-1RA的关节内给药导致血清清除速度减慢,并使突液度增加了25倍.
- 在16天内,catIL-1RA在开拓培养物中显著阻止了IL-1诱导的软骨代谢,表现优于Anakinra.
结论:
- 与Anakinra相比,catIL-1RA表现出优越的关节保留,而不会影响受体结合.
- 结合CPC的生物制品代表了增强疾病修饰性OA药物 (DMOADs) 联合生物可用性的有希望的方法.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
437
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
437
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
454
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
454
01:29Inflammatory Bowel Disease IV: Pharmacological Management
439
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
439
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
405
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
405
01:24T Cell Types and Functions
2.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.1K